Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Liabilities (2019 - 2025)

Keros Therapeutics' Total Liabilities history spans 7 years, with the latest figure at $34.9 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 21.3% year-over-year to $34.9 million; the TTM value through Dec 2025 reached $34.9 million, down 21.3%, while the annual FY2025 figure was $34.9 million, 21.3% down from the prior year.
  • Total Liabilities reached $34.9 million in Q4 2025 per KROS's latest filing, down from $39.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $55.7 million in Q1 2025 to a low of $7.8 million in Q2 2021.
  • Average Total Liabilities over 5 years is $28.7 million, with a median of $30.2 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: skyrocketed 163.82% in 2023, then fell 21.3% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $12.1 million in 2021, then skyrocketed by 143.09% to $29.4 million in 2022, then rose by 28.8% to $37.8 million in 2023, then grew by 17.25% to $44.3 million in 2024, then dropped by 21.3% to $34.9 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Total Liabilities are $34.9 million (Q4 2025), $39.2 million (Q3 2025), and $50.4 million (Q2 2025).